Supernus and Indivior agree to merge as Supernus reports second-quarter growth

Supernus Pharmaceuticals said on August 3, 2026 that it had reached an agreement to merge with Indivior Pharmaceuticals, Inc., creating a diversified CNS biopharmaceutical company with significant scale.¹ The deal is structured as an all-stock merger of equals under a definitive agreement between the two companies.¹ The companies held a joint call the same day to discuss the transaction, and Indivior intends to file a Form S-4 registration statement with the SEC that will include a joint proxy statement/prospectus for stockholders of both companies.¹

On the pipeline side, Supernus said its regulatory submission to the FDA for a second supplier for ONAPGO remains on track for the third quarter of 2026, with potential approval by mid-year 2027.¹ Since ONAPGO's launch, approximately 2,600 enrollment forms have been submitted by approximately 720 prescribers as of the end of July 2026.¹

In its epilepsy program, the Phase 2b study of SPN-817 at 3mg and 4mg twice-daily doses is ongoing, targeting enrollment of about 258 adult patients with treatment-resistant focal seizures.¹ For depression, the Phase 2b trial of SPN-820 in about 200 adults with major depressive disorder will test 2400mg given twice weekly as an add-on to baseline antidepressant therapy, examining safety, tolerability, and speed of symptom improvement.¹ For ADHD, Supernus expects to start a Phase 1 single- and multiple-ascending dose study of SPN-443 in healthy adult volunteers in the second half of 2026.¹

Financially, the company said it is raising its full-year 2026 financial guidance,¹ and reported cash, cash equivalents, and current marketable securities of approximately $372.1 million as of June 30, 2026, up from $308.7 million at year-end 2025, mainly due to cash generated from operations.¹